CTMX peer analysis
CytomX Therapeutics (CTMX) against its competitors: price, today's move, 1-year return and market value side by side.
- CTMX's peers: ADAG (Adagene), ADCT (ADC Therapeutics), CLDX (Celldex Therapeutics), MGNX (MacroGenics), NRIX (Nurix Therapeutics), PYXS (Pyxis Oncology), STRO (Sutro Biopharma), VRXA (Veraxa Biotech).
CTMX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ADAG Adagene | $2.01 | 10.44% | 11.05% | $75.67M |
| ADCT ADC Therapeutics | $1.28 | -1.54% | -68.16% | $180.05M |
| CLDX Celldex Therapeutics | $27.40 | -2.00% | 9.95% | $2.15B |
| MGNX MacroGenics | $1.98 | -0.01% | 39.43% | $126.53M |
| NRIX Nurix Therapeutics | $12.85 | -5.51% | -10.33% | $1.40B |
| PYXS Pyxis Oncology | $1.81 | 7.74% | -60.39% | $216.49M |
| STRO Sutro Biopharma | $8.60 | -1.38% | -5.49% | $142.77M |
| VRXA Veraxa Biotech | $1.03 | 0.00% | – | $145.65M |
| XNCR Xencor | $33.24 | -2.26% | 110.78% | $2.49B |
| ZYME Zymeworks | $26.14 | -2.68% | 15.66% | $1.82B |
| CTMX CytomX Therapeutics | $2.04 | -0.34% | -43.72% | $445.41M |